Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Loss of the epithelial marker CDX1 predicts poor prognosis in early-stage CRC patients

  • Solé Font, Laura|||0000-0002-3195-0565
  • Lobo-Jarne, Teresa|||0000-0002-1632-438X
  • Cabré-Romans, Júlia-Jié
  • González, Antón
  • Fernández, Lierni
  • Marruecos, Laura|||0000-0002-4206-709X
  • Guix, Marta|||0000-0002-2143-0697
  • Cuatrecasas, Miriam|||0000-0003-3063-0110
  • López, Sandra
  • Bellosillo Paricio, Beatriz|||0000-0002-5335-2726
  • Torres, Ferran|||0000-0002-7355-7913
  • Iglesias, Mar|||0000-0002-2274-4671
  • Bigas Salvans, Anna|||0000-0003-4801-6899
  • Espinosa, Lluis|||0000-0002-2897-4099
Background: We have previously shown that non-curative chemotherapy imposes fetal conversion and high metastatic capacity to cancer cells. From the set of genes differentially expressed in Chemotherapy Resistant Cells, we obtained a characteristic fetal intestinal cell signature that is present in a group of untreated tumors and is sufficient to predict patient prognosis. A feature of this fetal signature is the loss of CDX1. Methods: We have analyzed transcriptomic data in public datasets and performed immunohistochemistry analysis of paraffin embedded tumor samples from two cohorts of colorectal cancer patients. Results: We demonstrated that low levels of CDX1 are sufficient to identify patients with poorest outcome at the early tumor stages II and III. Presence tumor areas that are negative for CDX1 staining in stage I cancers is associated with tumor relapse. Conclusions: Our results reveal the actual possibility of incorporating CDX1 immunostaining as a valuable biomarker for CRC patients.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Enhancing immunotherapy through -1 upregulation, the promising combination of anti--1 plus m inhibitors

  • Hernández-Prat, Anna|||0000-0002-8233-1035
  • Rodriguez-Vida, Alejo|||0000-0002-7304-6857
  • Cardona, Laura
  • Qin, Mengjuan|||0000-0001-7014-7188
  • Arpí-Llucià, Oriol
  • Soria-Jiménez, Luis|||0000-0002-2182-8953
  • Menéndez, Sílvia|||0000-0002-9116-8743
  • Quimis, Fabricio Gerel
  • Galindo, Miguel
  • Arriola, Edurne|||0000-0001-8960-7519
  • Salido, Marta|||0000-0001-9988-5977
  • Juanpere-Rodero, Nuria
  • Rojo, Federico|||0000-0001-9989-0290
  • Muntasell i Castellví, Aura|||0000-0003-2894-0486
  • Albanell Mestres, Joan|||0000-0003-1239-4580
  • Rovira, Ana|||0000-0003-1301-2599
  • Bellmunt, Joaquim|||0000-0003-2328-3421
Immune checkpoint inhibitors (ICIs) targeting the programmed cell death protein 1 (PD-1)/programmed cell death 1 ligand 1 (PD-L1) pathway have transformed urothelial cancer (UC) therapy. The correlation between PD-L1 expression and ICI effectiveness is uncertain, leaving the role of PD-L1 as a predictive marker for ICI efficacy unclear. Among several ways to enhance the efficacy of ICI, trials are exploring combining ICIs with serine/threonine-protein kinase mTOR (mTOR) inhibitors in different tumor types. The potential interaction between mTOR inhibitors and PD-L1 expression in UC has not been well characterized. In our study, we investigated how phosphoinositide 3-kinase (PI3K)/AKT/mTOR pathway inhibitors (TAK-228, everolimus and TAK-117) affect PD-L1 expression and function in preclinical bladder cancer cell models. TAK-228 increased cell surface levels of glycosylated PD-L1 in all but one of the seven cell lines, regardless of baseline levels. TAK-228 promoted the secretion of epidermal growth factor (EGF) and interferon-β (IFNβ), both linked to PD-L1 protein induction. Blocking EGF and IFNβ receptors reversed the TAK-228-induced PD-L1 increase. Additionally, TAK-228 enhanced IFN-γ-induced PD-L1 expression and intracellular HLA-I levels in some cells. TAK-228-treated bladder cancer cells exhibited resistance to the cytotoxic effects of peripheral blood mononuclear cells (PBMCs) and cluster of differentiation 8 (CD8)+ T cells. The addition of an anti-PD-L1 antibody diminished this resistance in T24 cells. Increased expression of PD-L1 under TAK-228 exposure was confirmed in patient-derived explants (PDEs) treated ex vivo. These preclinical findings suggest that mTOR inhibition with TAK-228 can increase PD-L1 levels, potentially impacting the specific immune response against UC cells. This highlights the rationale for exploring the combination of mTOR inhibitors with ICIs in patients with advanced UC. mTOR inhibition with TAK-228 can increase PD-L1 levels, potentially impacting the specific immune response against bladder cancer cell lines.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Enhancing human NK cell antitumor function by knocking out SMAD4 to counteract TGFβ and activin A suppression

  • Rea, Anna|||0000-0003-1307-8045
  • Santana-Hernández, Sara|||0000-0001-7440-8445
  • Villanueva, Javier
  • Sanvicente-García, Marta|||0000-0002-4508-2834
  • Cabo, Mariona
  • Suarez-Olmos, Jesús
  • Quimis, Fabricio
  • Qin, Mengjuan|||0000-0001-7014-7188
  • Llorens, Eduard
  • Blasco-Benito, Sandra
  • Torralba-Raga, Lamberto
  • Perez, Lorena
  • Bhattarai, Bishan
  • Alari Pahissa, Elisenda|||0000-0001-7424-5383
  • Georgoudaki, Anna-Maria
  • Balaguer, Francesc|||0000-0002-0206-0539
  • Juan, Manel|||0000-0002-3064-1648
  • Pardo, Julián|||0000-0003-0154-0730
  • Celià-Terrassa, Toni|||0000-0002-0615-8744
  • Rovira, Ana|||0000-0003-1301-2599
  • Möker, Nina
  • Zhang, Congcong|||0000-0003-3693-4705
  • Colonna, Marco|||0000-0001-5222-4987
  • Spanholtz, Jan|||0000-0001-7152-6956
  • Malmberg, Karl-Johan|||0000-0002-8718-9373
  • Montagut, Clara
  • Albanell Mestres, Joan|||0000-0003-1239-4580
  • Güell, Marc|||0000-0003-4000-7912
  • López-Botet, Miguel|||0000-0003-4882-065X
  • Muntasell i Castellví, Aura|||0000-0003-2894-0486
Transforming growth factor beta (TGFβ) and activin A suppress natural killer (NK) cell function and proliferation, limiting the efficacy of adoptive NK cell therapies. Inspired by the partial resistance to TGFβ of NK cells with SMAD4 haploinsufficiency, we used CRISPR-Cas9 for knockout of SMAD4 in human NK cells. Here we show that SMAD4 NK cells were resistant to TGFβ and activin A inhibition, retaining their cytotoxicity, cytokine secretion and interleukin-2/interleukin-15-driven proliferation. They showed enhanced tumor penetration and tumor growth control, both as monotherapy and in combination with tumor-targeted therapeutic antibodies. Notably, SMAD4 NK cells outperformed control NK cells treated with a TGFβ inhibitor, underscoring the benefit of maintaining SMAD4-independent TGFβ signaling. SMAD4 conferred TGFβ resistance across diverse NK cell platforms, including CD19-CAR NK cells, stem cell-derived NK cells and ADAPT-NK cells. These findings position SMAD4 knockout as a versatile and compelling strategy to enhance NK cell antitumor activity, providing a new avenue for improving NK cell-based cancer immunotherapies.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

p53 wild-type colorectal cancer cells that express a fetal gene signature are associated with metastasis and poor prognosis

  • Solé Font, Laura|||0000-0002-3195-0565
  • Lobo-Jarne, Teresa|||0000-0002-1632-438X
  • Álvarez-Villanueva, Daniel
  • Alonso-Marañón, Josune
  • Guillén, Yolanda|||0000-0001-8673-6470
  • Guix, Marta|||0000-0002-2143-0697
  • Sangrador, Irene
  • Rozalén, Catalina
  • Vert, Anna
  • Barbachano, Antonio|||0000-0002-1248-5143
  • Lop Gros, Joan|||0000-0002-9442-5688
  • Salido, Marta|||0000-0001-9988-5977
  • Bellosillo Paricio, Beatriz|||0000-0002-5335-2726
  • García-Romero, Raquel
  • Garrido, Marta
  • González Miranda, Jessica|||0000-0001-7732-1564
  • Martínez-Iniesta, María
  • López-Arribillaga, Erika|||0000-0002-9451-6635
  • Salazar, Ramón
  • Torres, Ferran|||0000-0002-7355-7913
  • Iglesias, Mar|||0000-0002-2274-4671
  • Celià-Terrassa, Toni|||0000-0002-0615-8744
  • Muñoz, Alberto|||0000-0003-3890-4251
  • Villanueva, Alejandro|||0000-0001-5164-0006
  • Bigas Salvans, Anna|||0000-0003-4801-6899
  • Espinosa, Lluis|||0000-0002-2897-4099
Current therapy against colorectal cancer (CRC) is based on DNA-damaging agents that remain ineffective in a proportion of patients. Whether and how non-curative DNA damage-based treatment affects tumor cell behavior and patient outcome is primarily unstudied. Using CRC patient-derived organoids (PDO)s, we show that sublethal doses of chemotherapy (CT) does not select previously resistant tumor populations but induces a quiescent state specifically to TP53 wildtype (WT) cancer cells, which is linked to the acquisition of a YAP1-dependent fetal phenotype. Cells displaying this phenotype exhibit high tumor-initiating and metastatic activity. Nuclear YAP1 and fetal traits are present in a proportion of tumors at diagnosis and predict poor prognosis in patients carrying TP53 WT CRC tumors. We provide data indicating the higher efficacy of CT together with YAP1 inhibitors for eradication of therapy resistant TP53 WT cancer cells. Together these results identify fetal conversion as a useful biomarker for patient prognosis and therapy prescription.